title: Endovascular management of a patient after SAH.
abstract: Treatment of acute aneurysmal subarachnoid hemorrhages consists of occluding the aneurysm to prevent rebleed, attempting to prevent vasospasm, and maintaining blood flow to the brain through vessels in vasospasm. Endovascular treatment has been shown to be as safe as, or safer, than surgical clipping for patients with SAH. Engineering solutions to our clinical problems continue to improve endovascular outcomes. This article reviews the current state of endovascular therapy.
authors.affiliation: Department of Radiology and Neurosurgery, Johns Hopkins Medical Institution, Baltimore, MD 21287, USA.
authors.forename: Stephen
authors.initials: S
authors.lastname: Chang
authors.forename: Abhishek
authors.initials: A
authors.lastname: Srinivas
authors.forename: Kieran
authors.initials: K
authors.lastname: Murphy
mesh_terms: D000784:Aortic Dissection / Q000628:therapy*; D017542:Aneurysm, Ruptured / Q000601:surgery / Q000628:therapy*; D002543:Cerebral Hemorrhage / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D002986:Clinical Trials as Topic; D004621:Embolization, Therapeutic / Q000379:methods; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D002532:Intracranial Aneurysm / Q000601:surgery / Q000628:therapy*; D019635:Neurosurgical Procedures; D010208:Papaverine / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D012008:Recurrence; D015607:Stents; D013345:Subarachnoid Hemorrhage / Q000150:complications / Q000601:surgery / Q000628:therapy*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use; D020301:Vasospasm, Intracranial / Q000188:drug therapy / Q000209:etiology; D014711:Vertebral Artery
chemical_list: D005343:Fibrinolytic Agents; D014665:Vasodilator Agents; D010208:Papaverine; D010959:Tissue Plasminogen Activator